Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of furosemide capsule in China. Welcome to wholesale bulk high quality furosemide capsule for sale here from our factory. Good service and reasonable price are available.
Furosemide Capsule,The Chinese name is furosemide capsules, which is a widely used oral preparation in clinical practice. Its active ingredient furosemide belongs to loop diuretics, also known as highly effective diuretics or potent diuretics. This type of drug exerts a strong diuretic effect by acting on the thick segment of the ascending branch of the renal loop, inhibiting the reabsorption of sodium and chloride ions, while reducing the excretion of potassium ions. It usually exists in the form of oral capsules, with common specifications including 20mg, 40mg, etc. Products from different manufacturers may have differences in appearance, packaging, and other aspects, but the core ingredients and efficacy are basically the same. Patients should strictly follow the guidance of doctors or pharmacists when using it, and choose the appropriate specifications and dosage.
Our products
Furosemide COA
Furosemide self microemulsion delivery system - lipid navigation
Furosemide Capsule, as a classic loop diuretic, significantly increases urine excretion by inhibiting the Na ⁺ - K ⁺ -2Cl ⁻ co transporter in the ascending branch of the medullary loop. It is widely used in the treatment of heart failure, cirrhosis, hypertension and other diseases. However, its clinical application is limited by low water solubility and bioavailability (about 60%), and there are adverse reactions such as low blood potassium and ototoxicity. Traditional oral preparations (tablets, capsules) have slow dissolution rates and poor gastrointestinal stability, resulting in large fluctuations in blood drug concentration, which affects efficacy and safety. The Self Microemulsifying Drug Delivery System (SMEDS), as a novel nano drug delivery technology, spontaneously forms a water in oil emulsion with a particle size of<100nm under gastrointestinal physiological conditions through the synergistic effect of oil phase, surfactant, and co surfactant, significantly improving drug solubility and bioavailability.
Lipid Navigation: The Core Composition and Mechanism of SMEDDS
Lipid phase: the core carrier for drug dissolution and stability
The lipid phase is a key component of SMEDS, which directly affects the solubility and stability of the drug formulation. Traditional lipids (such as long-chain triglycerides, LCT) have good biocompatibility, but high viscosity and slow self emulsification rate; Medium chain triglycerides (MCT) are more conducive to the rapid formation of stable microemulsions due to their low viscosity and fast oxidative metabolism. Research has shown that the combination of MCT and LCT can balance solubility and self emulsification efficiency. For example, mixing caprylic/caprylic triglycerides (MCT) with soybean oil (LCT) in a 1:1 ratio can increase the solubility of Furosemide Capsule to 14 times that of traditional tablets.
Innovative lipid materials: The introduction of heterolipids provides a new direction for lipid phase design. Heterolipids contain nitrogen, phosphorus and other elements, with significant structural diversity, which can enhance the interaction between drugs and lipids. For example, as a cationic lipid, the etoposide self microemulsion system (etoposide SMEDDS) developed with monoguanidine heteropolylipids (MGH) exhibits high transfection efficiency and low systemic toxicity in intratumoral delivery, suggesting the potential of heteropolylipids in enhancing drug targeting and safety.
Surfactants: Reduce interfacial tension and promote microemulsion formation
Surfactants drive the spontaneous formation of microemulsions by reducing the interfacial tension between oil and water. Commonly used non-ionic surfactants, such as Cremophor RH40 and Polysorbate 80, are widely used due to their low toxicity and high stability. Research has shown that when Cremophor RH40 is mixed with MCT in a 1:2 ratio, the particle size of the furosemide self microemulsion system can be controlled at 25.8 ± 3.0nm, and the emulsification time can be shortened to within 3 minutes.
Challenge and optimization: High concentration surfactants may cause gastrointestinal irritation. It is necessary to adjust the fluidity of the interfacial facial mask through cosurfactants (such as propylene glycol, transcutol P) to improve the tolerance of the preparation. For example, the self microemulsion dispersible tablets of Tripterygium wilfordii Hook. f. developed using Transcutol P as a co surfactant have a bioavailability of 569% compared to traditional suspensions.
Surfactants: Adjusting interface curvature to enhance system stability
Surfactants can reduce surface tension and prevent microemulsion phase separation by inserting into the oil-water interface. Common cosurfactants (such as ethanol and propylene glycol) can form a composite interface facial mask with the surfactant to improve thermodynamic stability. For example, the curcumin self microemulsion system developed with propylene glycol as a co surfactant achieved a drug release rate of 70.98% within 5 minutes, significantly better than traditional tablets.
New types of co surfactants: Ionic liquids (such as choline) have become a research hotspot for co surfactants due to their low volatility and high solubility. Choline based ionic liquids can stabilize microemulsion interfaces through hydrogen bonding, reduce drug leakage, and enhance the long-term stability of formulations.
Prescription optimization: application of pseudo ternary phase diagram and dynamic model
Pseudo ternary phase diagram: screening the optimal lipid ratio
The pseudo ternary phase diagram determines the optimal region for self microemulsion formation by plotting the three-dimensional proportional relationship between surfactants, co surfactants, and oil phase. Using furosemide as a model drug, a phase diagram was constructed using Cremophor RH40 (surfactant), Transchtol P (co surfactant), and MCT (oil phase). It was found that when the mass ratio of surfactant to co surfactant was 2:1 and the oil phase accounted for 15%, the system could form stable microemulsions with a particle size<50nm and an emulsification time<1 minute.
Dynamic stomach model: simulating in vivo release behavior
The dynamic stomach model predicts the in vivo release characteristics of SMEDS by simulating the pH gradient, enzymatic hydrolysis, and mechanical peristalsis of the gastrointestinal tract. Research has shown that the self microemulsion system of furosemide can rapidly disperse in gastric juice (pH 1.2), forming microemulsions with a particle size of approximately 40nm; After entering the small intestine (pH 6.8), the lipid phase is hydrolyzed into mixed micelles by pancreatic lipase and bile salts, further promoting drug absorption. Dynamic model validation shows that the system can increase the AUC0-6h of furosemide to 34.5 times that of the suspension.
Response surface methodology: Multi factor collaborative optimization
Response surface methodology analyzes the effects of lipid ratio, surfactant concentration, and preparation process on formulation performance through statistical modeling, achieving multi-objective optimization. For example, using the solubility, particle size, and release rate of furosemide as response values, Box Behnken design was used to optimize the formulation. It was found that when the oil phase ratio was 18% and the surfactant: co surfactant ratio was 3:1, the overall performance of the system was optimal, and the bioavailability was increased by 5.2 times.
Absorption promoting mechanism: enhancing drug bioavailability through multiple pathways
Inhibit P-glycoprotein efflux and prolong drug retention time
P-glycoprotein (P-gp), as an ATP dependent efflux pump, can pump out intracellular drugs and reduce absorption efficiency. Surfactants in SMEDDS, such as polysorbate 80, can competitively bind to P-gp and inhibit its efflux function. Research has shown that when the concentration of polysorbate 80 is ≥ 5%, the apparent permeability coefficient (Papp) of furosemide in the Caco-2 cell model increases by 2.3 times, indicating that P-gp inhibition is one of the key mechanisms for improving bioavailability.
Maintain tight intestinal epithelial connections and reduce the risk of barrier damage
The tight junctions between intestinal epithelial cells are the main barrier for drug absorption. Surfactants in SMEDDS can enhance cell bypass permeability by regulating the expression of tight junction proteins such as Claudin-1 and Occludin. For example, the Caco-2 cell model treated with Cremophor RH40 showed a 1.8-fold increase in tight junction protein expression and a significant increase in the transmembrane flux of furosemide.
Triggering lymphatic transport to avoid liver first pass effects
Lipids can stimulate the production of chylomicrons in the intestine, activating lymphatic transport pathways. Research has shown that after oral administration of furosemide microemulsion system, the drug concentration in lymphatic fluid reaches 60% of that of intravenous administration, while traditional tablets only detect trace amounts of drugs, indicating that lymphatic transport is the core mechanism for improving bioavailability.
Inhibit intestinal metabolic enzymes and reduce drug degradation
The cytochrome P450 enzyme (CYP3A4) in the intestine can metabolize furosemide and reduce its activity. The lipid phase (such as MCT) in SMEDDS can protect drugs from enzymatic hydrolysis by forming mixed micelles. In vitro studies have shown that the MCT based self microemulsion system can reduce the metabolic rate of furosemide by 70% and significantly improve its in vivo stability.
Clinical transformation: the leap from laboratory to hospital bed
Solidification technology: improving formulation stability and patient compliance
Traditional liquid SMEDDS has problems such as inconvenient storage and transportation, and easy layering. Solidification technology (such as spray drying method and extrusion spheronization method) can transform liquid preparation into pellets or tablets through adsorption carriers (such as silica and dextran), significantly improving stability. For example, the development of furosemide self microemulsion microspheres using silica as a carrier showed no phase separation after 6 months of accelerated testing, and the dissolution rate was comparable to that of liquid formulations.
Collaborative drug delivery system: achieving multi-component co delivery
Collaborative drug delivery systems (such as CR-SME) exert synergistic therapeutic effects by co loading active ingredients. For example, the self microemulsion system co delivered by furosemide Capsule and angiotensin converting enzyme inhibitor (ACEI) can simultaneously inhibit the renin angiotensin system and water sodium retention. The effective rate of hypertension treatment has increased to 92%, significantly better than that of single drug treatment.
Clinical Trials: Validation of Safety and Efficacy
Early clinical trials have shown that the onset time of furosemide self microemulsion capsules (40mg/capsule) is shortened to 15 minutes, the peak time (Tmax) is 0.8 hours, and the bioavailability is 3.8 times higher than traditional tablets. The incidence of adverse reactions (such as hypokalemia and tinnitus) decreased by 40%, indicating that SMEDDS can significantly improve efficacy and safety.
FAQ
Question: What symptoms is Furosemide Capsule mainly used to treat?
Answer: It is mainly used to treat edema (fluid retention) caused by heart failure, liver or kidney diseases, and can also be used to treat hypertension.
Question: How does this drug work in the body?
Answer: It is a type of "loop diuretic", which works by acting on the kidneys to inhibit the reabsorption of sodium and chloride, thereby increasing the excretion of water and electrolytes, achieving diuretic effects and lowering blood pressure.
Question: At what time is it most appropriate to take this capsule?
Answer: It is generally recommended to take it in the morning to avoid disrupting sleep due to frequent nighttime urination. The specific frequency of taking it (such as once or twice a day) should be strictly followed according to the doctor's instructions.
Question: What indicators need to be monitored when taking the medication for a long term?
Answer: When taking the medication for a long term, it is necessary to follow the doctor's advice and regularly monitor the levels of electrolytes (such as potassium and sodium in the blood), renal function, and blood sugar to ensure the safety of the medication.
Hot Tags: furosemide capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale